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Background: Acute heart failure negatively affects short-term outcomes of patients with 
acute coronary syndrome (ACS). Therefore, reliable and non-invasive assessment of pul-
monary congestion is needed to select patients requiring more intensive monitoring and 
therapy. Since plasma levels of natriuretic peptides are influenced by myocardial isch-
emia, they might not reliably reflect congestion in the context of ACS. The novel endothe-
lial biomarker, soluble CD146 (sCD146), presents discriminative power for detecting the 
cardiac origin of acute dyspnea similar to that of natriuretic peptides and is associated 
with systemic congestion. We evaluated the performance of sCD146 for the assessment of 
pulmonary congestion in the early phase of ACS.
Methods: One thousand twenty-one consecutive patients with ACS were prospectively en-
rolled. Plasma levels of sCD146, brain natriuretic peptide (BNP), and high-sensitive tropo-
nin T were measured within 24 hr after the onset of chest pain. Pulmonary congestion on 
chest radiography was determined and classified in three groups according to the degree 
of congestion. 
Results: Nine hundred twenty-seven patients with ACS were analyzed. Ninety-two (10%) 
patients showed signs of pulmonary edema on chest radiography. Plasma levels of 
sCD146 reflected the radiological severity of pulmonary congestion. Higher plasma levels 
of sCD146 were associated with the worse degree of pulmonary congestion. In contrast to 
BNP, sCD146 levels were not affected by the level of troponin T.
Conclusions: The novel endothelial biomarker, sCD146, correlates with radiological sever-
ity of pulmonary congestion in the early phase of ACS and, in contrast to BNP, is not af-
fected by the amount of myocardial cell necrosis.
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INTRODUCTION
Acute coronary syndrome (ACS) is a common precipitating factor 
of acute heart failure (AHF), and the presence of pulmonary con-
gestion in patients with ACS negatively affects short term out-
comes [1, 2]. Reliable and non-invasive assessment of pulmonary 
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congestion is of importance to select patients in need of more in-
tensive monitoring and therapy. The use of biomarkers, in particu-
lar natriuretic peptides, was advocated for this purpose. However, 
levels of circulating natriuretic peptides are influenced by the 
amount of myocardial ischemia and, therefore, may not accu-
rately reflect pulmonary congestion in the context of ACS [3, 4].
It was recently shown that soluble CD146 (sCD146), an endo-
thelial biomarker of systemic congestion, has a discriminative 
power to detect the cardiac origin of acute dyspnea similar to 
that of natriuretic peptides [5]. The aim of this study was the 
evaluation of sCD146 for the assessment of the severity of pul-
monary congestion in the early phase of ACS.
METHODS
One thousand twenty-one consecutive patients who had ACS 
and were admitted to the coronary care unit (CCU) of the Cardi-
ology Department of the University Hospital of Brno (Czech Re-
public) from July 2009 to November 2012 were enrolled. The 
diagnosis of ACS was based on appropriate symptoms in con-
junction with consistent changes on electrocardiogram, i.e., ST-
segment elevation or depression, new left bundle branch block, 
or negative T wave [6]. Exclusion criteria were as follows: age 
>85 yr or estimated life expectancy due to non-cardiovascular 
reasons <12 months; known or newly diagnosed malignancy, 
inflammatory disease, or connective-tissue disease; distance 
from the place of residence to the hospital of >100 km; absence 
of coronary stenosis with reduction of the intraluminal diameter 
>50% on coronary angiography. Venous blood samples were 
drawn immediately on hospital admission before percutaneous 
coronary intervention (PCI) for standard biochemical and hema-
tological analyses as well as sCD146 measurement. Troponin T 
and brain natriuretic peptide (BNP) were measured in blood 
drawn exactly 24 hr after the onset of chest pain. Samples were 
centrifuged within 10 min in a refrigerated centrifuge and stored 
at -80°C. Troponin T was analyzed with the high-sensitive assay 
(Roche Diagnostics, Basel, Switzerland; normal values <0.014 
µg/L), BNP was assessed by using the AxSYM BNP-Microparti-
cle Enzyme Immunoassay (Abbott Laboratories, Chicago, IL, 
USA; normal values <100 pg/mL), and sCD146 levels were de-
termined by ELISA (CY-QUANT ELISA sCD146, Biocytex, Mar-
seille, France; normal values <320 ng/mL [7]). Pulmonary con-
gestion was assessed by conventional chest radiography at ad-
mission. Images were evaluated by certified radiologists and 
classified in three groups: no or mild congestion, interstitial pul-
monary edema, and alveolar pulmonary edema.
Written informed consent was obtained from all subjects be-
fore their participation in the study. The study was performed in 
observation of national laws and in accordance with the ethical 
standards of the Declaration of Helsinki, and was approved by 
the Ethics Committee of Faculty Hospital Brno (Brno, Czech 
Republic).
Values are expressed as median (interquartile range [IQR]) or 
as number (percentage), as appropriate. Three groups were 
compared with the Chi-square or the Kruskal-Wallis H-test, as 
appropriate. For statistically significant differences between the 
groups, subsequent pairwise comparisons were performed by 
using Dunn’s procedure with Bonferroni correction of the P 
value for multiple comparisons. ROC curve was analyzed to as-
sess diagnostic performances of biomarkers. The null hypothe-
sis was rejected with an adjusted two-sided P <0.05. All analy-
ses were performed by using IBM SPSS Statistics, Version 21.0. 
(IBM Corp, Armonk, NY, USA).
RESULTS
One thousand twenty-one patients presenting with ACS were 
prospectively screened. Patients without chest radiography at 
admission (n=94; 9%) were excluded from this analysis. Base-
line characteristics of the 927 patients included in the study are 
summarized in Table 1.
Patients were subsequently classified in three groups accord-
ing to the degree of pulmonary congestion on chest radiography 
at admission: no or mild congestion (n=835), interstitial edema 
(n=72), and alveolar edema (n=20). 
Patients with severe pulmonary congestion presented more 
often with non-ST-elevation myocardial infarction (NSTEMI); 
were older; had higher prevalence of diabetes, atrial fibrillation, 
and peripheral artery disease; had higher creatinine levels; and 
lower diastolic blood pressure at admission compared with the 
other subgroups. Patients with no or mild congestion had lower 
heart rate, lower inflammation parameters, and lower glucose 
than the patients with severe congestion. Of note, interstitial 
edema was associated with higher troponin T levels than the 
other subgroups. 
Patients with pulmonary congestion (interstitial or alveolar 
edema) presented an increased risk of in-hospital mortality 
compared with patients without or with mild pulmonary conges-
tion (5.6% and 10.0% vs. 0.5%, P <0.001). There was also a 
trend toward longer hospital stay with increasing pulmonary 
congestion, although pairwise comparisons were not statistically 
significant.
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Table 1. Baseline characteristics of the patients
Total 
N=927







Age (yr) 61 (55-67) 61 (55-67) 63 (55-68) 70 (59-73) 0.010
Male gender 707 (76%) 643 (77%) 50 (69%) 14 (70%) 0.281
Height (cm) 174 (168-179) 174 (168-180) 170 (168-179) 170 (165-174) 0.120
Weight (kg) 85 (75-95) 85 (75-95) 82 (76-90) 83 (74-97) 0.582
Systolic blood pressure (mmHg) 140 (120-160) 140 (120-160) 135 (113-155) 135 (103-151) 0.071
Diastolic blood pressure (mmHg) 80 (70-90) 80 (70-90) 80 (70-90) 70 (63-80) 0.008
Heart rate (/min) 76 (66-87) 75 (66-86) 82 (74-105) 87 (73-98) <0.001
Type of acute coronary syndrome 0.022
   Unstable angina 36 (4%) 35 (4%) 1 (1%) 0 (0%)
   NSTEMI 278 (30%) 248 (30%) 18 (25%) 12 (60%)
   STEMI 613 (66%) 552 (66%) 53 (74%) 8 (40%)
Risk factors
   Hypertension 508 (55%) 459 (55%) 35 (49%) 14 (70%) 0.224
   Dyslipidemia 380 (41%) 339 (41%) 31 (43%) 10 (50%) 0.653
   Diabetes 206 (22%) 171 (21%) 24 (33%) 11 (55%) <0.001
   Active smoking 424 (46%) 384 (46%) 34 (49%) 6 (30%) 0.597
   Family history 192 (28%) 179 (29%) 11 (24%) 2 (20%) 0.718
Previous myocardial infarction 107 (12%) 99 (12%) 7 (10%) 1 (5%) 0.562
Previous PCI 83 (9%) 80 (10%) 2 (3%) 1 (5%) 0.125
Previous CABG 22 (2%) 18 (2%) 4 (6%) 0 (0%) 0.149
Previous stroke 49 (5%) 38 (5%) 9 (13%) 2 (10%) 0.010
Peripheral artery disease 53 (6%) 41 (5%) 7 (10%) 5 (25%) <0.001
COPD 39 (4%) 35 (4%) 2 (3%) 2 (10%) 0.362
Atrial fibrillation 25 (3%) 19 (2%) 3 (4%) 3 (15%) 0.002
Laboratory values at admission
   Hemoglobin (g/L) 143 (133-153) 143 (133-153) 142 (129-157) 137 (113.5-149) 0.170
   Leucocytes (×109/L) 10.9 (8.7-13.7) 10.7 (8.6-13.3) 12.4 (9.7-16.5) 13.4 (10.9-17.8) <0.001
   Sodium (mmol/L) 140 (137-141) 140 (137-141) 139 (137-141) 138 (137-142) 0.196
   Potassium (mmol/L) 4 (3.7-4.4) 4 (3.7-4.4) 4.1 (3.8-4.4) 4.5 (4.1-5.0) 0.002
   Glucose (mmol/L) 7.6 (6.3-10) 7.5 (6.2-9.7) 9 (7.8-12.1) 13 (7.5-17.1) <0.001
   Creatinine (µmol/L) 82 (71-97) 82 (70-96) 84 (75-98) 103 (81-131) 0.002
   Troponin T* (µg/L) 1.41 (0.372-3.78) 1.34 (0.33-3.52) 3.47 (1.22-7.00) 1.16 (0.52-3.66) <0.001
   CRP* (mg/L) 18 (6-62) 15 (6-51) 70 (24-175) 66 (39-163) <0.001
Length of stay (days) 5 (4-7) 5 (4-7) 6 (4-9) 7 (5-12) 0.007
In-hospital mortality 10 (1.1%) 4 (0.5%) 4 (5.6%) 2 (10.0%) <0.001
*Reported BNP and Troponin T values at 24 hr after admission; CRP  values are at 48 hr after admission.
Abbreviations: BNP, brain natriuretic peptide; CABG, coronary artery bypass graft surgery; COPD, chronic obstructive pulmonary disease; CRP, C-reactive 
protein; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction. 
For the overall population, the median level of sCD146 was 
320 ng/mL (IQR 251-398 ng/mL, range 95-2,866 ng/mL) and 
the median level of BNP was 263 pg/mL (IQR 125-473 pg/mL, 
range 10-11,567 pg/mL). 
Fig. 1 shows that median plasma levels of BNP were higher 
in patients with interstitial (679 pg/mL, IQR 355-1,097 pg/mL) 
or alveolar (665 pg/mL, IQR 267-1,214 pg/mL) pulmonary 
edema than the patients without or with mild signs of conges-
Kubena P, et al.
sCD146, marker of severity of pulmonary congestion
http://dx.doi.org/10.3343/alm.2016.36.4.300 www.annlabmed.org  303
Fig. 1. Plasma levels of BNP and sCD146 according to the severity 
of pulmonary congestion. Increasing radiological evidence of pul-
monary congestion is associated with higher levels of sCD146. 
Plasma levels of BNP show higher dispersion and do not reflect the 
severity of pulmonary congestion. Median and interquartile range 
are displayed.








No or mild congestion Interstitial edema Alveolar edema
Pulmonary congestion




P =0.042 P =0.047
Fig. 2. Plasma levels of BNP and sCD146 according to troponin T 
levels. Increasing levels of troponin T are associated with higher 
BNP, but similar or lower levels of sCD146. Median and interquar-
tile range are displayed.







1st tertile 2nd tertile 3rd tertile
Troponin T
 BNP (pg/mL)      sCD146 (ng/mL)
P <0.001
P <0.001 P <0.001
P =0.015
P =0.017 NS
tion (251 pg/mL, IQR 119-430 pg/mL). No difference between 
patients with interstitial and alveolar pulmonary edema was ob-
served (P values shown in Fig. 1).
Fig. 1 further illustrates that plasma levels of sCD146 were 
less variable and better associated with the radiological severity 
of pulmonary congestion than BNP: Circulating sCD146 levels 
presented a stepwise increase with increasing degree of pulmo-
nary congestion. Median plasma levels of sCD146 in patients 
without or with mild signs of congestion, interstitial edema, and 
alveolar edema were 316 ng/mL (IQR 249-388 ng/mL), 348 ng/
mL (IQR 267-478 ng/mL), and 438 ng/mL (IQR 346-690 ng/
mL), respectively. Based on ROC curve analysis, circulating 
sCD146 levels could discriminate between interstitial and alveo-
lar edema better than BNP levels (AUC 0.71, 95% confidence 
interval 0.56-0.85 vs. 0.51, 95% confidence interval 0.34-0.68).
Fig. 2 shows the relationship between BNP levels, sCD146 
levels, and myocardial necrosis. BNP levels were associated 
with the level of troponin T. When the population was split into 
three groups according to troponin T levels, BNP  values were 
higher in the second and third tertiles of troponin T than the first 
tertile (P <0.001). In contrast to BNP levels, sCD146 levels were 
not increased, and even slightly decreased, in the second and 
third tertiles of troponin T compared with baseline.
DISCUSSION 
The present study confirmed the potential of sCD146 as a bio-
marker for the assessment of systemic congestion. Indeed, in 
ACS patients, circulating sCD146 levels reflected the severity of 
pulmonary congestion without being affected by the level of 
myocardial necrosis.
CD146 is a component of the endothelial junction expressed 
in endothelial cells and its soluble form (sCD146) is considered 
as a marker of endothelial damage [7]. We recently demon-
strated that sCD146 positively correlated with the inferior vena 
cava diameter in patients with AHF [5]. We further demon-
strated that pulmonary edema was also positively correlated 
with the level of myocardial expression of CD146 in a pre-clini-
cal model of sub-AHF [5]. In this study, we showed a positive 
relationship between the level of sCD146 and the severity of 
pulmonary congestion in 927 patients with ACS. This might be 
related to a greater level of “chronic” endothelial dysfunction as 
suggested by the higher prevalence of peripheral vascular dis-
eases and diabetes. The positive relationship between sCD146 
and pulmonary congestion, observed a few hours after ACS on-
set, may also be related to the acute alteration of the ischemic 
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left ventricle, leading to acute diastolic dysfunction, increase in 
post-capillary pulmonary pressure, and pulmonary edema. Fur-
ther studies should assess the time course of sCD146, espe-
cially its decay after diuretic therapy, in relation to pulmonary 
congestion to ascertain the role of pulmonary vascular stretch in 
sCD146 release.
Our study also showed a positive relationship between tropo-
nin T and BNP levels, but not with sCD146. BNP is known to 
increase in the presence of myocardial ischemia [3, 4]. 
In contrast, the lack or even the negative association of 
sCD146 with myocardial necrosis is a novel observation. It sug-
gests that cardiac myocytes are unlikely to be the main source 
of sCD146 in patients with ACS. Altogether, our data suggest an 
extra-cardiac source of sCD146 (possibly in the post-capillary 
pulmonary vessels) in patients with pulmonary edema. 
Since relevant pulmonary congestion complicates the course 
of one of ten patients presenting with ACS and, as confirmed in 
our study, negatively influences short-term outcomes, sCD146 
may help emergency physicians, cardiologists, and intensivists 
to assess and monitor pulmonary congestion in patients with 
ongoing ACS.
Our study has some limitations. First, data were derived from 
a single-center prospective cohort and the subgroups of patients 
presenting radiological evidence of pulmonary congestion, in 
particular alveolar edema, were rather small, despite a consider-
able number of included patients. A generalization of the find-
ings may need confirmation in multi-centric cohorts. Secondly, 
pulmonary congestion was assessed by conventional chest radi-
ography at admission by one experienced, certified radiologist. 
Although this is a common clinical practice, this method might 
not be very accurate in assessing pulmonary congestion. In par-
ticular, “hemodynamic congestion”, which often precedes the 
redistribution of fluids into the lungs, may be present without ra-
diological signs of pulmonary edema [8]. The results of this 
study should be confirmed using alternative non-invasive (flow 
of the pulmonary vein, lung ultrasound, and CT scan) or inva-
sive (pulmonary catheter) methods for the assessment of left-
sided congestion [9]. Third, this cohort did not specifically in-
clude patients combining ACS with other pulmonary diseases 
(e.g., pulmonary infection) and, therefore, no analysis of the 
performance of sCD146 for the differentiation of pulmonary 
opacities of different origins could be performed. However, since 
other causes of pulmonary opacity are much less frequent than 
pulmonary edema in patients with ACS, this differentiation could 
be of limited clinical value. Fourth, plasma sCD146 levels were 
measured in blood samples drawn immediately on hospital ad-
mission before PCI, whereas concentrations of troponin T and 
BNP were measured in blood samples collected exactly 24 hr 
after the onset of chest pain. This design was chosen to assess 
peak levels of both troponin T and BNP according to their dy-
namic of release.
In conclusion, the novel endothelial biomarker, sCD146, re-
flects the radiological severity of pulmonary congestion better 
than BNP in patients with ACS and, in contrast to BNP, is not 
affected by the amount of myocardial cell necrosis. Additional 
studies are needed in patients with AHF secondary to ACS and 
to other causes to confirm these results.
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